Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H
Frauenklinik and Poliklinik, Technischen Universität München, Klinikum rechts der Isar, Germany.
Cancer Res. 1994 May 15;54(10):2527-30.
The serine protease urokinase-type plasminogen activator (uPA) plays a key role in tumor-associated proteolysis in malignant solid tumors. Proteolytic activity of uPA is controlled by its naturally occurring plasminogen activator inhibitor type 1. As an initial observation, a correlation of enzymatic uPA activity in breast cancer cytosols with prognosis was described in 1988 (Duffy et al., Cancer (Phila.), 62: 531-533, 1988). A pronounced prognostic impact of uPA, independent of classical risk parameters, was then first demonstrated in detergent-extracted (Triton X-100) breast cancer tissues by applying enzyme-linked immunosorbent assay techniques (Jänicke et al., Lancet, 2: 1049, 1989; Fibrinolysis, 4:69-78, 1990; Duffy et al., Cancer Res., 50: 6827-6829, 1990). In addition, not only uPA but also plasminogen activator inhibitor type 1 were shown to be of prognostic value in breast cancer (Jänicke et al., Semin. Thromb. Hemostasis, 17: 303-312, 1991; Breast Cancer Res. Treat., 24: 195-208, 1993). Subsequently, the prognostic value of uPA and plasminogen activator inhibitor type 1 was also confirmed in studies using archived "cytosol fractions" of breast cancer tissues (Foekens et al., Cancer Res., 52: 6101-6105, 1992; Spyratos et al., J. Natl. Cancer Inst., 84: 1266-1272, 1992; Grondahl-Hansen et al., Cancer Res., 53: 2513-2521, 1993; Sumiyoshi et al., Int. J. Cancer, 50: 345-348, 1992). A direct comparison of both methods with regard to prognosis, however, was lacking. We therefore prepared both the detergent-treated tissue extracts and the cytosol fractions from the same breast cancer specimens to allow a direct comparison of both methods. In 247 breast cancer patients investigated, the Triton X-100-extracted tissues revealed about twice as much uPA antigen (uPATx: median, 2.32 ng/mg protein) than the cytosol fractions (uPAcyt: median, 1.07 ng/mg protein). In contrast, the presence of Triton X-100 did not result in an increase of PAI-1 (PAI-1Tx: median, 6.34 ng PAI-1/mg protein) compared to the cytosol fractions (PAI-1cyt: median, 7.15 ng PAI-1/mg protein). Good correlations between uPATx and uPAcyt (R = 0.72) and between PAI-1Tx and PAI-1cyt (R = 0.88) were observed. Furthermore, PAI-1 and uPA are moderately correlated with each other (uPATx versus PAI-1Tx: R = 0.40; uPAcyt versus PAI-1cyt: R = 0.39). The prognostic power of uPA showed its best advantage in Triton X-100-extracted tissues (RR = 3.22), most pronounced in the subgroups of node-negative and premenopausal patients, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
丝氨酸蛋白酶尿激酶型纤溶酶原激活剂(uPA)在恶性实体瘤的肿瘤相关蛋白水解过程中起关键作用。uPA的蛋白水解活性受其天然存在的1型纤溶酶原激活剂抑制剂的控制。作为初步观察,1988年有人描述了乳腺癌细胞溶质中uPA的酶活性与预后的相关性(达菲等人,《癌症》(费城),62:531 - 533,1988)。随后,通过应用酶联免疫吸附测定技术,首次在去污剂提取(Triton X - 100)的乳腺癌组织中证明了uPA具有独立于经典风险参数的显著预后影响(亚尼克等人,《柳叶刀》,2:1049,1989;《纤维蛋白溶解》,4:69 - (此处原文有误,应为78)78,1990;达菲等人,《癌症研究》,50:6827 - 6829,1990)。此外,不仅uPA,1型纤溶酶原激活剂抑制剂在乳腺癌中也显示出预后价值(亚尼克等人,《血栓与止血研讨会》,17:303 - 312,1991;《乳腺癌研究与治疗》,24:195 - 208,1993)。随后,在使用存档的乳腺癌组织“细胞溶质部分”的研究中也证实了uPA和1型纤溶酶原激活剂抑制剂的预后价值(福肯斯等人,《癌症研究》,52:6101 - 6105,1992;斯皮拉托斯等人,《美国国家癌症研究所杂志》,84:1266 - 1272,1992;格伦达尔 - 汉森等人,《癌症研究》,53:2513 - 2521,1993;住吉等人,《国际癌症杂志》,50:345 - 348,1992)。然而,缺乏关于这两种方法在预后方面的直接比较。因此,我们从相同的乳腺癌标本中制备了去污剂处理的组织提取物和细胞溶质部分,以便直接比较这两种方法。在对247例乳腺癌患者的研究中,Triton X - 100提取的组织中uPA抗原(uPATx:中位数,2.32 ng/mg蛋白质)比细胞溶质部分(uPAcyt:中位数,1.07 ng/mg蛋白质)多约两倍。相比之下,与细胞溶质部分(PAI - 1cyt:中位数,7.15 ng PAI - 1/mg蛋白质)相比,Triton X - 100的存在并未导致PAI - 1增加(PAI - 1Tx:中位数,6.34 ng PAI - 1/mg蛋白质)。观察到uPATx与uPAcyt之间(R = 0.72)以及PAI - 1Tx与PAI - 1cyt之间(R = 0.88)具有良好的相关性。此外,PAI - 1和uPA彼此之间呈中度相关(uPATx与PAI - 1Tx:R = 0.40;uPAcyt与PAI - 1cyt:R = 0.39)。uPA的预后能力在Triton X - 100提取的组织中显示出最佳优势(相对风险 = 3.22),分别在淋巴结阴性和绝经前患者亚组中最为明显。(摘要截断于400字)